Baboolal Keshwar, McEwan Philip, Sondhi Seema, Spiewanowski Piotr, Wechowski Jaroslaw, Wilson Karen
Department of Nephrology and Transplantation, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK.
Nephrol Dial Transplant. 2008 Jun;23(6):1982-9. doi: 10.1093/ndt/gfm870. Epub 2008 Jan 3.
The UK National Health Service (NHS) will fund renal services using Payment by Results (PbR), from 2009. Central to the success of PbR will be the creation of tariffs that reflect the true cost of medical services. We have therefore estimated the cost of different dialysis modalities in the Cardiff and Vale NHS Trust and six other hospitals in the UK.
We used semi-structured interviews with nephrologists, head nurses and business managers to identify the steps involved in delivering the different dialysis modalities. We assigned costs to these using published figures or suppliers' published price lists. The study used mixed costing methods. Dialysis costs were estimated by a combination of microcosting and a top-down approach. Where we did not have access to detailed accounts, we applied values for Cardiff.
The most efficient modalities were automated peritoneal dialysis (APD) and continuous ambulatory peritoneal dialysis (CAPD), the mean annual costs of which were pound21 655 and pound15 570, respectively. Hospital-based haemodialysis (HD) cost pound35 023 per annum and satellite-unit-based HD cost pound32 669. The cost of home-based HD was pound20 764 per year (based on data from only one unit). The main cost drivers for PD were the costs of solutions and management of anaemia. For HD they were costs of disposables, nursing, the overheads associated with running the unit and management of anaemia.
Renal tariffs for PbR need to reflect the true cost of dialysis provision if choices about modalities are not to be influenced by erroneous estimates of cost. Knowledge of the true costs of modalities will also maximize the number of established renal failure patients treated by dialysis within the limited funds available from the NHS.
英国国家医疗服务体系(NHS)自2009年起将采用按结果付费(PbR)的方式为肾脏服务提供资金。按结果付费成功的关键在于制定反映医疗服务真实成本的收费标准。因此,我们估算了加的夫和韦尔国民保健服务信托基金以及英国其他六家医院不同透析方式的成本。
我们通过对肾病学家、护士长和业务经理进行半结构化访谈,以确定提供不同透析方式所涉及的步骤。我们使用已公布的数据或供应商公布的价格清单为这些步骤分配成本。该研究采用了混合成本核算方法。透析成本通过微观成本核算和自上而下的方法相结合来估算。在我们无法获取详细账目时,我们采用加的夫的数值。
最有效的透析方式是自动化腹膜透析(APD)和持续性非卧床腹膜透析(CAPD),其平均年度成本分别为21,655英镑和15,570英镑。医院内血液透析(HD)每年的成本为35,023英镑,卫星单位血液透析的成本为32,669英镑。家庭血液透析的成本为每年20,764英镑(仅基于一个单位的数据)。腹膜透析的主要成本驱动因素是溶液成本和贫血管理成本。对于血液透析而言,主要成本驱动因素是一次性用品成本、护理成本、单位运营相关的间接费用以及贫血管理成本。
如果透析方式的选择不受成本错误估计的影响,则按结果付费的肾脏收费标准需要反映透析服务的真实成本。了解不同透析方式的真实成本也将使在英国国家医疗服务体系有限资金范围内接受透析治疗的终末期肾衰竭患者数量最大化。